Hormones & diabetes

Osteoporosis Medications: Bisphosphonates and Other Options

Save

Bisphosphonates like alendronate (Fosamax) are first-line osteoporosis medications — they slow bone breakdown and reduce fracture risk. Denosumab (Prolia) is an injectable alternative given every six months. Anabolic agents like teriparatide or romosozumab build new bone and are reserved for severe cases.

Last updated: July 2026History

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

How do osteoporosis medications work?

Bone is continuously remodeled: specialized cells called osteoclasts break old bone down, and osteoblasts build new bone. In osteoporosis, breakdown outpaces building, leading to weaker bone over time. Medications target this imbalance in different ways:

  • Antiresorptive agents slow the breakdown of bone by suppressing osteoclast activity. This includes bisphosphonates and denosumab.
  • Anabolic agents directly stimulate osteoblasts to form new bone. This includes teriparatide (a fragment of parathyroid hormone) and abaloparatide.
  • Dual-action agents both build and antiresorb. Romosozumab (Evenity) inhibits sclerostin, a protein that suppresses bone formation, while also reducing breakdown 1.

What are bisphosphonates, and who are they for?

Bisphosphonates are the most widely used first-line treatment for postmenopausal osteoporosis. The most common are:

  • Alendronate (Fosamax) — taken orally once weekly
  • Risedronate (Actonel) — taken orally weekly or monthly
  • Ibandronate (Boniva) — oral monthly or IV every 3 months
  • Zoledronic acid (Reclast) — IV infusion once yearly

The Endocrine Society clinical practice guideline identifies bisphosphonates as generally first-line for most postmenopausal women with osteoporosis or high fracture risk, with substantial long-term safety data 1.

Who should not take them? People with significantly reduced kidney function may not be candidates, particularly for IV formulations. Oral bisphosphonates can irritate the esophagus; people with difficulty swallowing or certain esophageal conditions should discuss alternatives.

Drug holidays: After several years of bisphosphonate therapy (typically 3–5 years for oral, 3 years for IV), some clinicians recommend a pause. The benefit persists in bone tissue for some time after stopping. The decision depends on initial fracture risk and treatment response 2.

What is Prolia (denosumab), and how does it compare to Fosamax?

Denosumab (Prolia) is a monoclonal antibody injected under the skin every six months by a healthcare provider. It works by blocking RANKL, the protein signal that drives osteoclasts to break down bone. Clinical trials show it reduces fracture risk at the spine, hip, and other sites 1.

Key differences from bisphosphonates: - Prolia does not accumulate in bone the way bisphosphonates do. This means the effect reverses relatively quickly if doses are missed or the drug is stopped. A 2025 review in the Journal of Bone and Mineral Research found that denosumab discontinuation causes a rapid rebound in bone turnover markers and has been associated with multiple vertebral fractures — sometimes occurring as soon as 8–16 months after the final injection 3. Stopping denosumab without transitioning to another medication is clinically dangerous. - Prolia is safe to use in people with kidney disease who cannot take bisphosphonates. - It is given by injection rather than taken as a pill.

Neither medication is inherently "better" — the choice depends on individual factors including kidney function, adherence preferences, cost, and fracture history.

When are anabolic (bone-building) treatments used?

Anabolic agents are typically reserved for people with severe osteoporosis — multiple fractures, very low T-scores, or those who have not responded adequately to antiresorptive therapy 12.

  • Teriparatide (Forteo) — daily injection for up to two years
  • Abaloparatide (Tymlos) — daily injection for up to two years
  • Romosozumab (Evenity) — monthly injection for one year; has a boxed warning about cardiovascular risk and should be used cautiously in people with a history of heart attack or stroke

Anabolic treatment is almost always followed by antiresorptive therapy (typically a bisphosphonate) to preserve the bone gained.

Who prescribes and manages osteoporosis treatment?

Osteoporosis is frequently managed by primary care clinicians for straightforward cases. Complex situations — severe osteoporosis, treatment-resistant cases, need for anabolic therapy, or significant comorbidities — are best evaluated by an endocrinologist, a specialist in hormone and metabolic bone disorders.

A Gale clinician can review your bone density results, discuss your fracture risk, refer you to the right specialist, and help you prepare for that appointment with any needed records or questions.

Common questions

Duration depends on the medication and your fracture risk. Bisphosphonates are often used for 3 to 5 years before reassessing whether a drug holiday is appropriate. Denosumab must be continued indefinitely or transitioned carefully to another agent. Anabolic agents are limited to 1 to 2 years. Your clinician will guide the timeline based on your bone density trends and fracture risk.

Common side effects of oral bisphosphonates include upper gastrointestinal discomfort (heartburn, nausea) if not taken correctly — they require remaining upright for 30 minutes after taking. Rare but notable concerns include atypical femur fracture and osteonecrosis of the jaw, both of which are uncommon, particularly with lower doses used for osteoporosis. IV bisphosphonates can cause a flu-like reaction after the first infusion that usually resolves within a day or two.

Estrogen-containing hormone therapy does protect bone and is FDA-approved for osteoporosis prevention. It is most appropriate for women who are also taking it for menopausal symptoms. Because of other health considerations, it is generally not used solely for bone density when other options are available. This decision involves a careful conversation with a clinician.

Calcium and vitamin D are important for bone health but are not a substitute for prescription treatment in someone already diagnosed with osteoporosis or high fracture risk. They are typically used alongside medication, not instead of it.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Important safety note for denosumab (Prolia)

  • —Do not stop Prolia without first talking to your clinician — abrupt discontinuation can cause rapid bone loss and multiple spine fractures
  • —Any new back pain, especially after stopping medication, should be evaluated promptly
  • —Report jaw pain, swelling, or non-healing sores in the mouth to your clinician — rare side effect of antiresorptive therapy

This article provides general information about medication classes and is not a recommendation for any specific drug. Osteoporosis treatment decisions require evaluation by a qualified clinician who knows your full medical history, bone density results, kidney function, and other medications. Gale can help you understand your results and connect you with the right specialist.

Did this answer your question?

References

  1. 1.Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019). Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. doi:10.1210/jc.2019-00221 ✓First-line bisphosphonate recommendation; denosumab efficacy for fracture reduction; anabolic agents reserved for severe osteoporosis; mechanism of each medication class
  2. 2.LeBoff MS, Greenspan SL, Insogna KL, et al. (2022). The clinician's guide to prevention and treatment of osteoporosis. Osteoporosis International. doi:10.1007/s00198-021-05900-y ✓Drug holiday guidance (3–5 years for oral bisphosphonates; 3 years for IV); anabolic agents for severe or treatment-resistant osteoporosis; sequential therapy after anabolics
  3. 3.Kumar S, Wang M, Kim AS, Center JR, McDonald MM, Girgis CM (2025). Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures. Journal of Bone and Mineral Research. doi:10.1093/jbmr/zjaf037 ✓Denosumab discontinuation causes rapid rebound in bone turnover; multiple vertebral fractures can occur as soon as 8–16 months after the final injection; need for careful transition to another agent on stopping

3 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library